{"schema_version":"1","generated_at":"2026-11-07T09:35:17.860Z","data_as_of":null,"url":"https://www.findmykol.com/kol/sarmad-sadeghi","json_url":"https://www.findmykol.com/kol/sarmad-sadeghi/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"sarmad-sadeghi","name":"Sarmad Sadeghi","credential":"MD, MS, PhD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"University of Southern California","institution_url":"https://www.findmykol.com/institution/university-of-southern-california","city":"Los Angeles","state":"CA","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1316104797","orcid":"0000-0003-2654-1991","openalex":"A5075022478"},"summary":"Sarmad Sadeghi is an Oncology physician affiliated with University of Southern California. OpenAlex indexes 95 publications with 542 citations (h-index 13); ClinicalTrials.gov lists 6 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":95,"cited_by_count":542,"h_index":13,"latest_activity_year":2026,"source":"works"},"trials":{"count":6,"shown":3,"withheld":3,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT06493552","title":"Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors","phase":"PHASE2/PHASE3","status":"RECRUITING","role":"Overall official","sponsor":"Vasgene Therapeutics, Inc","source_url":"https://clinicaltrials.gov/study/NCT06493552","trial_url":"https://www.findmykol.com/trial/NCT06493552"},{"nct":"NCT04579224","title":"Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","role":"Overall official","sponsor":"National Cancer Institute (NCI)","source_url":"https://clinicaltrials.gov/study/NCT04579224","trial_url":"https://www.findmykol.com/trial/NCT04579224"},{"nct":"NCT04486781","title":"A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma","phase":"PHASE2","status":"UNKNOWN","role":"Overall official","sponsor":"Vasgene Therapeutics, Inc","source_url":"https://clinicaltrials.gov/study/NCT04486781","trial_url":"https://www.findmykol.com/trial/NCT04486781"}],"source":"trials"},"payments":{"company_count":2,"program_years":{"first":2021,"last":null},"rows_total":14,"shown":3,"withheld":11,"rows":[{"payer":"Pfizer","program_year":2025,"amount_usd":359754,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1316104797"},{"payer":"Eisai","program_year":2025,"amount_usd":112000,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1316104797"},{"payer":"Pfizer","program_year":2024,"amount_usd":1741376.22,"payment_count":10,"source_url":"https://openpaymentsdata.cms.gov/search?query=1316104797"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1316104797","source":"payments"},"funding":{"award_count":1,"fiscal_years":{"first":2025,"last":2026},"rows_total":2,"shown":2,"withheld":0,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"R01CA293348","title":"Synergistic immune response after EphrinB2 inhibition & PD-1 antibody therapy in urothelial carcinoma.","fiscal_year":2026,"amount_usd":"679846","organization":"UNIVERSITY OF SOUTHERN CALIFORNIA","source_url":"https://reporter.nih.gov/quickSearch/R01CA293348"},{"project":"R01CA293348","title":"Synergistic immune response after EphrinB2 inhibition & PD-1 antibody therapy in urothelial carcinoma.","fiscal_year":2025,"amount_usd":"712735","organization":"UNIVERSITY OF SOUTHERN CALIFORNIA","source_url":"https://reporter.nih.gov/quickSearch/R01CA293348"}],"source":"grants"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Integrating NECTIN4 Amplification with Membranous NECTIN4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma","year":2026,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1078-0432.ccr-26-0093","status":"verified"},{"title":"End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco-25-01608","status":"verified"},{"title":"EphB4-ephrin-B2 are targets in castration resistant prostate cancer","year":2025,"journal":"British Journal of Cancer","source_url":"https://doi.org/10.1038/s41416-025-02942-5","status":"verified"},{"title":"The outcomes of salvage robotic radical prostatectomy following radiation versus focal therapy: Does the primary treatment modality matter?","year":2025,"journal":"BJUI Compass","source_url":"https://doi.org/10.1002/bco2.70019","status":"verified"},{"title":"A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2025.43.5_suppl.tps887","status":"verified"}],"source":"works"},"contact":{"address_1":"1441 EASTLAKE AVE","address_2":"NOR 8302E","city":"Los Angeles","state":"CA","zip":"900890112","phone":"323-865-3000","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1316104797","source":"identity"},"similar":[{"name":"David Liebeskind","slug":"david-liebeskind","institution":"University of Southern California","specialty":"Neurology","url":"https://www.findmykol.com/kol/david-liebeskind","json_url":"https://www.findmykol.com/kol/david-liebeskind/profile.json"},{"name":"Siamak Daneshmand","slug":"siamak-daneshmand","institution":"University of Southern California","specialty":"Urology","url":"https://www.findmykol.com/kol/siamak-daneshmand","json_url":"https://www.findmykol.com/kol/siamak-daneshmand/profile.json"},{"name":"David Freyer","slug":"david-freyer","institution":"University of Southern California","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/david-freyer","json_url":"https://www.findmykol.com/kol/david-freyer/profile.json"},{"name":"Andrew Moshfeghi","slug":"andrew-moshfeghi","institution":"University of Southern California","specialty":"Ophthalmology","url":"https://www.findmykol.com/kol/andrew-moshfeghi","json_url":"https://www.findmykol.com/kol/andrew-moshfeghi/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":3,"payments":11,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2023-11-27","provider_certified":"2020-10-31","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}